Lesson 6 - Choosing the Right Medication

1. Introduction

Why This Topic Matters

Knowing the pharmacology of ADHD medication is important. Knowing which medication to choose for the individual patient is the more clinically demanding skill.

By this stage, we have considered stimulant and non-stimulant medications separately. In practice, however, patients do not arrive asking us to demonstrate our knowledge of Methylphenidate, Lisdexamfetamine, Atomoxetine or Guanfacine in isolation.

They arrive with a clinical question:

"Which treatment is most appropriate for me?"

Answering that question requires more than following a medication hierarchy.

Guidelines provide an essential framework, but medication choice also needs to take account of the individual's:

• age

• ADHD symptoms and functional impairment

• treatment goals

• previous medication exposure

• previous treatment response

• adverse-effect vulnerability

• physical health

• psychiatric comorbidity

• sleep and appetite

• daily routine

• required duration of symptom control

• substance use

• risk of misuse or diversion

• ability to adhere to treatment

• preferences and concerns

The objective is therefore not to identify the theoretical "best ADHD medication".

There is no single medication that is best for every patient.

The objective is to identify the most appropriate treatment to try next for this particular person, at this particular stage of their treatment pathway.

From Guidelines to Individual Patients

Clinical guidelines provide a starting point for medication selection.

They help clinicians determine which treatments should usually be considered first and what should happen when treatment is ineffective or poorly tolerated.

But guidelines do not remove the need for clinical judgement.

Consider three patients with ADHD.

A 9-year-old child requires symptom control throughout the school day and has difficulty remembering medication.

A 22-year-old university student has a history of misusing stimulants obtained from friends.

A 41-year-old professional needs symptom coverage from early morning until the evening because their difficulties affect both work and parenting.

All three may have ADHD.

All three may potentially benefit from medication.

But the prescribing considerations are different.

The diagnosis tells us what condition we are treating.

The formulation helps us decide how best to treat this person.

Medication Choice Is More Than Choosing a Molecule

When clinicians discuss medication choice, they sometimes focus entirely on the active drug:

Methylphenidate or Lisdexamfetamine?

Stimulant or non-stimulant?

In practice, there are several levels of decision-making.

First:

Which medication class is appropriate?

Then:

Which medicine within that pathway?

Then:

Which formulation?

Then:

What duration of effect is required?

Then:

How will treatment be titrated and evaluated?

A patient may respond well to Methylphenidate but poorly to a particular release profile.

Another may obtain excellent benefit from a long-acting stimulant but find that the duration does not match their working day.

Another may respond therapeutically but experience adverse effects that make continued treatment unacceptable.

Medication choice therefore includes drug, formulation, timing and fit with the patient's life.

Think in Terms of Treatment Fit

A useful concept is treatment fit.

The right medication should fit several dimensions simultaneously.

Clinical fit

Is it appropriate for the patient's ADHD and current place in the treatment pathway?

Physical-health fit

Are there medical factors that influence the risk-benefit assessment?

Psychiatric fit

How might comorbidity influence treatment selection, monitoring or interpretation of response?

Functional fit

Will the expected duration of effect cover the periods when impairment matters?

Practical fit

Can the patient reliably take the medication as prescribed?

Safety fit

Are misuse, diversion, interactions or other risks relevant?

Preference fit

Does the patient understand and accept the proposed treatment?

A medication can be pharmacologically effective and still be a poor overall fit.

Previous Treatment Response Is Valuable Clinical Information

When selecting medication, one of the most useful pieces of information is often what happened with previous treatment.

But this information needs to be specific.

Avoid accepting:

"Methylphenidate didn't work."

Instead establish:

• which preparation was used

• what dose was reached

• how long it was taken

• whether adherence was adequate

• whether any benefit occurred

• how long benefit lasted

• which adverse effects emerged

• why treatment was stopped

There is a substantial difference between:

no therapeutic response despite an adequate trial

and

clear therapeutic response but unacceptable adverse effects.

There is also a difference between:

medication failure

and

formulation failure.

This distinction can substantially influence what should be tried next.

Comorbidity Influences Choice, But Avoid Simplistic Rules

ADHD commonly coexists with:

• anxiety

• depression

• autism

• tic disorders

• sleep disorders

• substance-use disorders

• eating difficulties

• other neurodevelopmental and psychiatric conditions

These conditions may influence medication selection and monitoring.

However, avoid turning comorbidity into simplistic prescribing rules.

For example:

"Anxiety means you cannot use a stimulant."

"Tics mean you must use a non-stimulant."

"Autism means stimulants will not work."

"Any history of substance misuse means stimulants are prohibited."

These statements are too simplistic.

Comorbidity should modify the clinical formulation and monitoring plan, not replace individual assessment.

Patient Preference Matters

Medication selection should involve shared decision-making.

Patients may have strong views about:

• stimulant medication

• controlled drugs

• appetite

• sleep

• duration of action

• taking medication at work or school

• dependence

• personality change

• long-term treatment

• non-stimulant alternatives

Some concerns will be based on accurate information.

Others may arise from misconceptions or previous experiences.

The clinician's role is not simply to say:

"This is the medication NICE recommends, so this is what you should take."

Nor is it to prescribe whichever medication the patient requests without considering the evidence.

The task is to explain:

what the reasonable options are

why one option may be preferable

what benefits might realistically be expected

what uncertainties remain

what risks and adverse effects need to be considered

and then reach an appropriate decision together.

The First Medication Does Not Have to Be the Final Medication

Another important message for patients is that medication selection is usually an iterative process.

The first medication chosen is often the best evidence-based starting point, not a prediction that it will definitely be the patient's optimal long-term treatment.

A medication trial may demonstrate:

• excellent response and good tolerability

• partial response

• insufficient duration

• unacceptable adverse effects

• no meaningful response

Each outcome provides information.

Treatment can then be refined.

This is why medication history should be regarded as clinical data, not simply a list of previous prescriptions.

Treatment Choice Changes Over Time

The right medication today may not remain the right medication indefinitely.

A child's needs may change when they move from primary to secondary school.

An adolescent may begin driving.

A university student may move into employment.

An adult may become a parent or start shift work.

Physical health may change.

Psychiatric comorbidity may emerge.

Other medication may be introduced.

The patient's priorities may also change.

Medication selection should therefore be reconsidered throughout treatment rather than treated as a once-only decision.

How This Lesson Fits Into the Overall Course

The preceding lessons have built the foundations required for rational medication selection.

We have considered:

diagnostic formulation

↓

explaining the diagnosis

↓

psychoeducation

↓

non-pharmacological management

↓

stimulant medication

↓

non-stimulant medication

We now bring those areas together.

Rather than asking:

"What does Methylphenidate do?"

or:

"What are the adverse effects of Atomoxetine?"

we move to the more clinically realistic question:

"Given everything I know about this patient, which medication is the most appropriate option to consider now, and why?"

This lesson will therefore examine how medication choice is influenced by:

• current guideline recommendations

• age and stage of treatment

• previous medication response

• stimulant versus non-stimulant considerations

• immediate-release versus modified-release preparations

• required duration of symptom control

• physical health

• cardiovascular considerations

• psychiatric comorbidity

• anxiety

• tics

• autism

• sleep and appetite

• substance misuse

• misuse and diversion risk

• drug interactions

• adherence

• patient preference

• lifestyle and occupational requirements

• inadequate response and poor tolerability

The aim is not to create a rigid prescribing algorithm.

It is to develop a structured method of clinical reasoning that allows doctors to explain and defend why a particular medication has been selected for a particular patient.

The central principle for this lesson is:

Do not ask which ADHD medication is best. Ask which medication provides the best evidence-based fit for this patient, given their treatment history, clinical formulation, functional needs, safety considerations and preferences.

2. Learning Outcomes

By the end of this lesson, learners should be able to:

1. Apply current clinical guidance to ADHD medication selection, identifying the appropriate place of stimulant and non-stimulant medications within treatment pathways for children, young people and adults.

2. Select an appropriate medication and formulation for an individual patient, taking account of age, symptom profile, functional impairment, required duration of effect, daily routine, adherence and previous treatment response.

3. Integrate physical health, psychiatric comorbidity and safety considerations into medication choice, including cardiovascular factors, sleep and appetite, anxiety, tic disorders, autism, substance misuse, potential drug interactions and the risk of medication misuse or diversion.

4. Interpret previous medication trials systematically, distinguishing inadequate dose or duration, insufficient therapeutic response, insufficient duration of effect, poor adherence, formulation-related problems and treatment-limiting adverse effects.

5. Use shared decision-making when selecting ADHD medication, explaining the reasonable treatment options, expected benefits, potential adverse effects, uncertainties and practical considerations while incorporating the patient's preferences and treatment goals.

6. Develop and justify an individualised medication plan, including the rationale for the chosen treatment, intended functional targets, approach to titration and monitoring, and the circumstances in which treatment should be optimised, changed or reconsidered.

3. The Lecture

Choosing Medication Is a Clinical Reasoning Exercise

When people first learn ADHD prescribing, there is a temptation to look for an algorithm:

ADHD → Drug A → if that fails, Drug B → if that fails, Drug C.

Guidelines are important, and we should know the recommended treatment sequence. But good prescribing is more sophisticated than moving mechanically through a list.

The question is not simply:

"Which medication comes first?"

It is:

"What is the most appropriate evidence-based medication to try next for this particular patient, and why?"

To answer that properly, you need to bring together:

• age

• current guideline position

• severity and pattern of impairment

• treatment goals

• required duration of effect

• previous medication trials

• physical health

• psychiatric comorbidity

• appetite and sleep

• substance use

• misuse or diversion risk

• adherence

• other medication

• practical circumstances

• patient preference

Think of medication choice as an extension of the diagnostic formulation.

You have already asked:

Why does this person have these difficulties?

Now you are asking:

Given those difficulties, what treatment best fits their needs?

Start With the Guideline Pathway

Before individualising treatment, know the standard treatment pathway.

For UK practice, NICE NG87 provides the core framework.

Children and Young People

For children aged 5 years and over and young people for whom medication is indicated, Methylphenidate is generally the first-line pharmacological treatment.

If an adequate trial of Methylphenidate has not produced sufficient benefit, Lisdexamfetamine may be considered.

If a patient responds to Lisdexamfetamine but cannot tolerate its longer duration of effect, Dexamfetamine may sometimes be considered.

If appropriate stimulant trials are not tolerated or have produced insufficient response, Atomoxetine or Guanfacine may become relevant.

Adults

For adults, Methylphenidate or Lisdexamfetamine are first-line pharmacological options.

If an adequate trial of one has produced insufficient benefit, switching to the other is generally considered.

Dexamfetamine may have a role where Lisdexamfetamine is effective but its longer duration is not well tolerated.

Atomoxetine becomes an important non-stimulant option where appropriate stimulant trials have not been tolerated or have produced insufficient response.

The precise pathway, licensing position and prescribing arrangements should always be checked against current guidance.

The first principle is therefore:

Start with the evidence-based pathway, then individualise within it.

Clinical judgement does not mean ignoring guidelines.

Equally, following guidelines does not mean abandoning clinical judgement.

The Medication-Selection Framework

When deciding what to prescribe, I would encourage you to work through seven questions.

Question 1: Where is the patient in the treatment pathway?

Is this:

• first pharmacological treatment?

• a switch after inadequate response?

• a switch because of adverse effects?

• treatment following several previous trials?

• a patient returning to treatment after a long interruption?

This immediately changes the available options.

Question 2: What are we trying to improve?

Define the treatment targets.

Question 3: When does the patient need symptom control?

Morning?

School hours?

Working day?

Evening?

Driving?

Parenting?

Question 4: What has happened with previous medication?

Benefit?

Duration?

Adverse effects?

Adherence?

Question 5: What clinical factors influence safety or tolerability?

Physical health?

Psychiatric comorbidity?

Appetite?

Sleep?

Substance use?

Interactions?

Question 6: What practical factors matter?

Can the patient take medication during the day?

Will they remember multiple doses?

Can medication be stored securely?

Question 7: What does the patient prefer?

Only after working through these questions are you really choosing medication.

Do Not Choose Medication Before Defining the Treatment Target

Imagine an adult says:

"I want medication because my ADHD is really bad."

Before selecting a drug, ask what really bad means.

Perhaps the main problems are:

• repeatedly missing deadlines

• inability to begin administrative work

• interrupting during meetings

• forgetting appointments

• unsafe impulsive driving

• difficulty completing household responsibilities

Those become treatment targets.

Now compare that with another adult whose main difficulties occur between 6pm and 10pm when they are looking after their children.

The diagnosis may be identical.

The required medication profile may not be.

Medication should be selected partly according to when clinically significant impairment occurs.

Duration of Effect Is Part of Medication Choice

One of the most common prescribing mistakes is choosing medication according to symptoms without considering the patient's day.

Ask:

"What time do you need to function well?"

That question is surprisingly powerful.

Consider a patient who:

• wakes at 6am

• drives to work at 7am

• works until 5pm

• collects children at 5:30pm

• helps with homework

• manages household responsibilities until 9pm

Medication that provides good symptom control from 9am until 3pm may be pharmacologically effective but functionally inadequate.

Now consider another patient whose main requirement is concentrated academic work between 9am and 2pm.

The same duration may be entirely appropriate.

Do not prescribe to the clock on the packet.

Prescribe to the patient's functional day.

Immediate-Release or Modified-Release?

This is not simply a pharmacokinetic question.

It is a practical clinical decision.

Modified-Release Medication

Modified-release preparations may offer advantages including:

• convenience

• fewer doses

• reduced need for medication administration during school or work

• potentially better adherence

• reduced stigma associated with taking medication publicly

• reduced opportunities for diversion in some circumstances

For many patients, these practical advantages are substantial.

Immediate-Release Medication

Immediate-release medication can sometimes be useful where:

• flexible timing is required

• shorter periods of symptom control are needed

• a particular part of the day requires additional coverage

• a longer duration of effect is poorly tolerated

• specialist titration strategies require greater flexibility

However, disadvantages can include:

• repeated dosing

• forgetting doses

• rebound between doses

• administration difficulties at school or work

• greater opportunities for misuse or diversion

The formulation should therefore fit both the pharmacological requirement and the patient's ability to use it safely and consistently.

Modified-Release Methylphenidate Is Not One Single Product

This deserves emphasis.

Different modified-release Methylphenidate preparations can have different proportions of immediate and delayed release and therefore different clinical profiles.

Two preparations containing the same total milligram dose may not produce identical:

• onset

• peak effect

• duration

• afternoon coverage

Do not think simply:

"Methylphenidate 36mg."

Think:

"Which Methylphenidate formulation, with what release profile, and why does that profile suit this patient?"

If a patient is stable on a particular modified-release preparation, apparently simple switching between products can alter the clinical effect.

Previous Medication Trials: Become a Clinical Detective

A patient arrives with a referral letter saying:

"Previous Methylphenidate ineffective."

Do not accept that as sufficient information.

Ask:

Which preparation?

What dose?

How long?

Was it taken consistently?

What improved?

How long did the benefit last?

What adverse effects occurred?

Why exactly was it stopped?

You may discover that "ineffective" actually means:

"It worked very well until lunchtime."

That is not necessarily medication failure.

It may be a duration problem.

Alternatively:

"It improved concentration considerably but caused unacceptable appetite suppression."

That is a tolerability problem.

Or:

"They prescribed it, but I only took it four times."

That is not an adequate therapeutic trial.

Six Reasons Why a Medication May Appear to Have Failed

When a medication is described as ineffective, consider six possibilities.

1. Inadequate Dose

The medication may never have been adequately titrated.

2. Inadequate Duration of Trial

Particularly relevant to non-stimulants.

3. Poor Adherence

The medication may not actually have been taken consistently.

4. Wrong Formulation

The drug may work but not for long enough or at the right times.

5. Genuine Pharmacological Non-response

An adequate trial may genuinely have produced insufficient benefit.

6. The Treatment Target Was Wrong

Perhaps the remaining difficulty is primarily driven by:

• anxiety

• depression

• sleep deprivation

• autism-related difficulties

• substance use

• environmental stress

• learning difficulties

• another condition

Increasing ADHD medication will not necessarily solve a problem that is not being driven by ADHD.

Do Not Use Medication Response as a Diagnostic Test

This point should now be familiar.

A patient who responds well to Methylphenidate does not thereby prove that they have ADHD.

A patient who fails to respond to Methylphenidate and Lisdexamfetamine does not thereby prove that they do not have ADHD.

Diagnosis is established through clinical assessment.

Medication response tells you about treatment response.

However, repeated treatment failure should make you reconsider the formulation.

Ask:

"What exactly are we trying to treat?"

That is good clinical medicine, not diagnostic backtracking.

Choosing Between Methylphenidate and Lisdexamfetamine

In adults, both may occupy a first-line position, so how do we think about the choice?

There is no universal answer.

Consider:

• previous response

• previous adverse effects

• required duration

• formulation characteristics

• misuse and diversion considerations

• appetite

• sleep

• other medication

• patient preference

• practical circumstances

If a patient previously had an excellent response to appropriately prescribed Methylphenidate with good tolerability, that is useful information.

If another patient previously experienced substantial benefit from an amphetamine preparation but little response to Methylphenidate, that is also useful information.

Medication history should influence future prescribing.

When One Stimulant Does Not Work

Do not conclude:

"Stimulants don't work for this patient."

Response to Methylphenidate does not reliably predict response to an amphetamine-based stimulant at an individual level.

If one class has been adequately tried without sufficient benefit, an appropriate trial of the alternative stimulant class may still be worthwhile where clinically indicated.

This is one reason careful documentation matters.

You need to know whether the previous trial was genuinely adequate before moving further through the treatment pathway.

When a Non-stimulant May Become the Better Fit

Atomoxetine or, in appropriate paediatric circumstances, Guanfacine may become relevant when:

• stimulant treatment is not tolerated

• adequate stimulant trials have produced insufficient benefit

• other clinical factors influence the risk-benefit assessment

But avoid thinking:

"Non-stimulant = safer option."

Instead ask:

"Does this medication's risk-benefit profile fit this patient better?"

Atomoxetine and Guanfacine have their own adverse effects and monitoring requirements.

Physical Health and Medication Choice

Before prescribing, ask whether physical health changes the risk-benefit calculation.

Relevant considerations can include:

• cardiovascular history

• pulse and blood pressure

• weight and growth

• appetite

• sleep

• other medical conditions

• current medication

• clinically relevant family history

The presence of a physical-health condition does not automatically prohibit medication.

It may instead change:

• which medication is preferred

• whether further assessment is required

• how cautiously treatment is titrated

• how closely treatment is monitored

Cardiovascular Considerations

Do not reduce cardiovascular assessment to:

"Stimulants increase blood pressure, therefore cardiovascular history means no stimulants."

The real question is:

What is the patient's actual cardiovascular risk?

Baseline assessment should identify relevant symptoms and history.

Particular concerns may warrant further assessment or specialist input.

Equally, routine investigations should not be ordered indiscriminately when current guidance does not indicate them.

The goal is proportionate assessment.

Remember also that non-stimulants are not cardiovascularly neutral.

Atomoxetine can increase pulse and blood pressure.

Guanfacine can reduce them and can produce hypotension, bradycardia and syncope.

Choosing a non-stimulant does not make cardiovascular thinking disappear.

Appetite, Weight and Growth

Suppose you are choosing medication for a child who is already significantly underweight and has longstanding feeding difficulties.

That should influence your thinking.

It does not necessarily mean that stimulant medication can never be used.

But appetite and growth become particularly important in:

• medication selection

• counselling

• baseline assessment

• titration

• monitoring

Now consider an adult with binge-eating behaviour who asks for a particular stimulant because they have heard it suppresses appetite.

That requires a different conversation.

ADHD medication should be selected to treat ADHD, not prescribed primarily as an unsupervised weight-management strategy.

Sleep

Sleep should be assessed before medication selection because untreated sleep problems can both resemble and worsen ADHD symptoms.

Ask:

• What time does the patient sleep?

• How long does sleep onset take?

• Is sleep restorative?

• Is there insomnia?

• Is there delayed sleep phase?

• Is there excessive daytime sleepiness?

• Is caffeine contributing?

• Could there be sleep-disordered breathing?

Then consider how medication timing and duration may interact with that pattern.

Do not automatically blame every subsequent sleep difficulty on medication.

But equally, do not ignore a clear temporal relationship between dose changes and worsening insomnia.

Anxiety

ADHD and anxiety frequently coexist.

A common prescribing myth is:

"If the patient has anxiety, avoid stimulants."

That is too simplistic.

Some patients experience worsening anxiety with stimulant treatment.

Others become less anxious when ADHD is effectively treated because they are:

• more organised

• missing fewer deadlines

• making fewer mistakes

• feeling less overwhelmed

Ask whether anxiety is:

a separate anxiety disorder

secondary to chronic ADHD-related difficulties

medication-related

or

a combination of these.

Medication selection should follow that formulation.

Depression

Depression also requires careful formulation.

A patient may present with:

• genuine comorbid depressive disorder

• demoralisation secondary to longstanding ADHD

• exhaustion from chronic functional difficulties

• both ADHD and depression

The relative severity of each condition matters.

If someone is acutely and severely depressed with significant risk, stabilising that presentation may take priority.

If depressive symptoms are largely associated with chronic failure, overwhelm and loss of confidence from untreated ADHD, effective ADHD treatment may improve part of the picture.

Do not use one diagnosis to erase the other.

Bipolar Disorder and Psychosis

These situations require greater caution.

If a patient has current mania or psychosis, the immediate priority is generally the acute psychiatric presentation rather than routine ADHD titration.

A historical diagnosis of bipolar disorder or psychotic illness requires careful review of:

• diagnostic history

• current stability

• previous episodes

• current treatment

• medication adherence

• previous response to ADHD medication

• risk of destabilisation

These are circumstances in which senior or specialist clinical judgement is particularly important.

Autism

ADHD commonly coexists with autism.

Autism does not mean that ADHD medication cannot be effective.

However, some autistic patients may experience:

• greater sensitivity to adverse effects

• difficulty describing internal effects

• sensory issues affecting medication administration

• rigid routines influencing adherence

• baseline eating or sleep difficulties

The response may therefore require particularly careful titration and observation.

Treat the ADHD where treatment is indicated.

Do not attempt to medicate autistic traits that are not the treatment target.

Tic Disorders

Another outdated rule is:

"Tics mean no stimulants."

The relationship is more nuanced.

ADHD and tic disorders frequently coexist, and tic severity naturally fluctuates.

If tics worsen during treatment, consider:

• baseline tic history

• timing

• natural fluctuation

• dose relationship

• functional impact

• whether ADHD benefit outweighs the change

Medication choice should be individualised rather than determined by the mere presence of a tic disorder.

Substance Misuse

Substance misuse requires careful judgement rather than blanket rules.

Ask:

• What substance?

• Current or historical?

• How frequent?

• What level of dependence?

• Is the patient stable?

• Is there evidence of prescription misuse?

• Is diversion likely?

• Can medication be stored safely?

• Is treatment being supervised appropriately?

Do not assume:

"Substance-use history = no ADHD medication."

But equally, do not prescribe controlled medication without addressing obvious risk.

The decision is a risk-benefit formulation.

Misuse and Diversion

When diversion risk matters, formulation becomes important.

Warning signs may include:

• repeated unexplained lost prescriptions

• requests for particular preparations without convincing clinical rationale

• escalating doses outside the agreed plan

• inconsistent accounts of medication use

• evidence of sharing or selling medication

• repeated early supply requests

None of these should automatically be interpreted as proof of misuse.

But they should prompt assessment.

Where misuse or diversion is a concern, consider:

• formulation

• quantity supplied

• prescribing arrangements

• storage

• supervision

• non-stimulant alternatives where appropriate

• specialist input

Do not ignore risk because the patient has a genuine ADHD diagnosis.

A genuine diagnosis and medication misuse can coexist.

Adherence Should Influence Medication Choice

A medication can only work if the patient can realistically take it.

Imagine a teenager who:

• regularly forgets medication

• refuses to visit the school office

• is embarrassed taking tablets in front of peers

A three-times-daily regimen may be pharmacologically possible but practically poor.

Now consider an adult working unpredictable shifts.

A rigid medication schedule may also be problematic.

Ask:

"Can this patient actually follow the treatment plan I am designing?"

If not, redesign it.

Driving

Driving is an important functional domain, particularly for adolescents and adults.

ADHD itself may affect:

• attention

• impulsivity

• risk-taking

• consistency of driving behaviour

When choosing medication, consider whether clinically important impairment extends into periods when the patient drives.

Medication duration may therefore have safety implications beyond work or study.

Patients should also receive appropriate advice regarding their legal responsibilities and the effects of both their condition and medication on safe driving.

Work, Education and Parenting

Do not define treatment coverage solely around work or school.

A patient may function adequately at work while medication is active but experience major difficulties when:

• commuting

• preparing meals

• managing finances

• supervising children

• completing household tasks

• maintaining relationships

Ask:

"When in your day does ADHD matter?"

Not merely:

"What hours do you work?"

Patient Preference and Shared Decision-Making

Medication selection should be collaborative.

Explain:

• why medication is being considered

• the reasonable options

• why one option may be preferred

• expected benefits

• common and important adverse effects

• monitoring

• duration of effect

• uncertainty

• alternatives

Then ask:

"What matters most to you when choosing between these options?"

One patient may prioritise all-day coverage.

Another may be particularly concerned about appetite.

Another may want to minimise medication administration during work.

Another may strongly prefer a non-stimulant after understanding the differences.

Patient preference is clinically relevant.

But shared decision-making does not mean prescribing any requested medication regardless of clinical appropriateness.

Clinical Example 1: The High-Functioning Professional

A 39-year-old solicitor with ADHD works from 8am until 6pm and has two young children.

Her main difficulties are:

• sustained attention during lengthy documents

• switching between competing tasks

• administrative procrastination

• impulsive interruptions

• severe disorganisation during the evening parenting routine

She asks:

"Which medication is strongest?"

That is not the right question.

You need to consider:

• first-line options

• required duration

• cardiovascular and psychiatric history

• sleep

• appetite

• previous medication exposure

• work demands

• evening parenting

• patient preference

A medication producing excellent control from 9am until 3pm may not meet her functional needs.

The clinical objective is not maximum pharmacological potency.

It is appropriate coverage with acceptable tolerability.

Clinical Example 2: The Child With Poor Appetite

An 8-year-old with ADHD has substantial classroom impairment.

He is also a very selective eater and his weight is already being monitored.

Medication may still be appropriate.

But appetite and growth now become particularly important in:

• baseline assessment

• treatment discussion

• medication selection

• titration

• monitoring

You would want a clear nutritional baseline and close follow-up.

The existence of an adverse-effect vulnerability does not automatically prohibit treatment.

It changes how thoughtfully you prescribe it.

Clinical Example 3: "Methylphenidate Didn't Work"

A 16-year-old is referred after "failed Methylphenidate".

You discover that she received a low dose of immediate-release Methylphenidate for five days.

She stopped because:

"It wore off."

That is not an adequate demonstration that Methylphenidate is ineffective.

The previous trial needs to be interpreted properly before moving further through the treatment pathway.

Medication histories should be analysed, not merely recorded.

Clinical Example 4: Substance Misuse History

A 28-year-old with well-established ADHD has a previous history of cocaine misuse but has been abstinent for two years.

He asks whether his history means he can never receive stimulant medication.

The answer should not be an automatic yes or no.

Assess:

• current stability

• current substance use

• treatment engagement

• previous prescription misuse

• diversion risk

• physical health

• psychiatric comorbidity

• safeguarding

• available formulations

• non-stimulant alternatives

• monitoring arrangements

The diagnosis does not remove risk.

The risk does not automatically remove all treatment options.

This is where clinical judgement matters.

Clinical Example 5: Good Effect, Wrong Formulation

A 12-year-old takes modified-release Methylphenidate.

Teachers report excellent improvement until early afternoon.

By the final two lessons:

• concentration deteriorates

• impulsivity returns

• homework is extremely difficult

The temptation is to say:

"Increase the dose."

But first ask:

Is the effect insufficient, or is the duration insufficient?

If the medication works very well while active, the active drug may be entirely appropriate.

The problem may be the release profile or duration of coverage.

This is a formulation problem, not necessarily a drug failure.

When Should You Change Medication?

Consider changing medication when there is:

Insufficient benefit

Despite an adequate trial and appropriate titration.

Unacceptable adverse effects

Even if some therapeutic benefit is present.

Inadequate overall benefit-risk balance

A medication may work but still not be worth continuing.

Practical incompatibility

The regimen may simply not fit the patient's life.

Significant safety concerns

The clinical situation may change.

Patient preference

Provided an alternative is clinically appropriate.

But before switching, document clearly:

What worked?

What did not?

What dose was reached?

How long was it tried?

What adverse effects occurred?

Why are we changing?

This information makes the next decision better.

When Should You Not Change Medication?

Do not change simply because:

• the starting dose has not worked

• the patient cannot "feel" the medication

• one difficult day occurred

• a rating-scale score has not normalised

• there is some residual ADHD

• another medication is perceived as "stronger"

• a friend takes something different

• an online discussion recommends another product

Treatment should be optimised according to clinical response, not medication fashion.

Partial Response

Partial response is common and requires careful interpretation.

Suppose ADHD symptoms improve by approximately half.

Ask:

• Which symptoms remain?

• Which areas of impairment remain?

• Is there room for further safe titration?

• Is duration adequate?

• Are adverse effects limiting?

• Are remaining difficulties actually due to ADHD?

• Would non-pharmacological intervention address the residual impairment?

The aim is not necessarily to eliminate every ADHD trait.

The aim is clinically meaningful improvement in symptoms and functioning with acceptable adverse effects.

The Best Medication Is Not Necessarily the Highest Dose

This principle should run through the entire pharmacology section of the course.

Do not titrate towards a number.

Titrate towards an outcome.

The correct dose is the dose at which the balance of:

benefit

and

tolerability

is optimal for the individual.

If 30mg produces excellent functional improvement and increasing to 40mg adds no meaningful benefit but worsens appetite and sleep, 40mg is not "better treatment" simply because it is a larger dose.

What If Nothing Seems to Work?

When several appropriate medication trials have failed, resist the temptation to keep moving automatically through increasingly complex pharmacology.

Return to the formulation.

Reconsider:

• diagnostic certainty

• adherence

• adequacy of previous trials

• sleep

• substance use

• anxiety

• depression

• autism

• learning difficulties

• environmental demands

• treatment expectations

• other medication

• physical health

• psychosocial stressors

Sometimes the answer is another medication.

Sometimes it is not.

Complex treatment failure is a signal to think more, not simply prescribe more.

A Practical Medication-Choice Model

A useful mental model is:

Step 1: Confirm the indication

Is medication appropriate?

↓

Step 2: Identify the guideline-supported options

What treatments are appropriate at this point in the pathway?

↓

Step 3: Define functional targets

What exactly are we trying to improve?

↓

Step 4: Map the patient's day

When is treatment required?

↓

Step 5: Review previous treatment

What has already been learned?

↓

Step 6: Identify modifiers

Physical health, psychiatric comorbidity, sleep, appetite, substance use, interactions and risk.

↓

Step 7: Consider practical fit

Formulation, adherence, administration, storage and lifestyle.

↓

Step 8: Incorporate patient preference

What matters to the patient?

↓

Step 9: Select and explain the treatment

Why this medication? Why this formulation?

↓

Step 10: Define the trial

Starting dose, titration, monitoring, functional targets and review point.

This produces a prescribing decision that is both clinically defensible and understandable to the patient.

How to Explain Your Choice to the Patient

A good medication recommendation should be explainable in ordinary language.

For example:

"There are two first-line stimulant options we could reasonably consider. Given that you need coverage across most of the working day and have no particular clinical reason to avoid either class, I think a long-acting preparation is the most practical starting point. We would begin cautiously, monitor your pulse, blood pressure, appetite and sleep, and increase only if necessary. The aim would be to see whether your concentration, task completion and impulsivity improve without troublesome adverse effects. If it does not suit you, that does not mean medication treatment has failed; we would review what happened and consider the alternatives."

That explanation demonstrates:

• guideline awareness

• individualisation

• realistic expectations

• monitoring

• shared decision-making

• contingency planning

That is what good prescribing sounds like.

Document the Rationale

The clinical record should make the medication choice understandable to another doctor.

Avoid:

"Start ADHD medication."

Prefer something closer to:

"Following discussion of pharmacological options, modified-release Methylphenidate selected as first-line treatment. Long-acting preparation preferred because clinically significant impairment extends across the school day and administration during school would be difficult. Baseline physical assessment satisfactory. Treatment targets include classroom task completion, reduced impulsive interruption and improved homework initiation. Benefits, common and important adverse effects and monitoring discussed."

The rationale matters.

Good documentation protects continuity of care and improves future prescribing decisions.

When Specialist Judgement Becomes Particularly Important

Seek experienced specialist input when medication selection becomes complicated by factors such as:

• significant cardiovascular disease

• current or previous psychosis

• bipolar disorder

• significant substance misuse

• complex eating pathology

• severe or unusual adverse effects

• substantial polypharmacy

• important drug interactions

• repeated treatment failure

• complex combination pharmacotherapy

• prescribing outside usual licensing or guideline pathways

• diagnostic uncertainty

Knowing when not to make a routine prescribing decision is part of competent prescribing.

The Central Prescribing Principle

There is no medication-selection rule that replaces formulation.

The same diagnosis can lead to different rational medication choices because patients differ in:

• treatment history

• physiology

• comorbidity

• functional demands

• risk

• preference

• response

The best treatment is therefore not necessarily:

the strongest medication

the newest medication

the longest-acting medication

or

the medication that works best on average.

It is the medication and formulation with the best evidence-based fit for the individual patient.

Key Learning Points

Medication selection should begin with current clinical guidance but should then be individualised.

Before choosing medication, establish:

where the patient is in the treatment pathway

what needs to improve

when symptom control is required

what previous medication trials have taught you

what physical and psychiatric factors influence treatment

whether misuse or diversion matters

whether the regimen is practically achievable

and

what the patient prefers.

Distinguish carefully between:

drug failure

dose failure

duration failure

formulation failure

adherence failure

and

treatment of the wrong target.

Comorbidity should influence clinical reasoning without becoming a collection of rigid prescribing rules.

Formulation matters. The active ingredient alone does not tell you when medication will work, how long it will last or whether it will fit the patient's day.

Patient preference should be incorporated through shared decision-making, but treatment must remain clinically appropriate and evidence-based.

If several medications appear to have failed, return to the formulation before escalating treatment complexity.

Above all:

Do not ask, "What is the best ADHD medication?"

Ask:

"What is the most appropriate medication and formulation for this patient, at this stage of treatment, given their functional needs, previous response, safety profile and preferences?"

That is the question that turns knowledge of ADHD pharmacology into good clinical prescribing.

4. Clinical Perspective

Choosing ADHD medication becomes easier when you stop trying to identify the theoretically perfect drug and instead make a series of smaller, clinically answerable decisions.

In practice, the most useful questions are often:

What are we trying to improve?

When does the patient need the medication to work?

What have previous medication trials already taught us?

What might make this option less safe or less tolerable?

Can the patient realistically follow this regimen?

What matters to the patient?

The quality of medication selection depends as much on these questions as it does on pharmacological knowledge.

Clinical Pearls

Choose for the Patient's Day, Not Just Their Diagnosis

Two patients with very similar ADHD symptoms may require different treatment strategies because their functional demands are different.

Ask:

"Talk me through a normal day. Where does ADHD cause the most difficulty?"

A school-aged child may primarily require coverage across the educational day.

An adult may need treatment while driving to work, throughout employment and again during evening parenting.

A university student may have an irregular timetable with substantial independent study.

The diagnosis identifies the condition.

The patient's life helps determine the required treatment profile.

"It Didn't Work" Is the Beginning of the Medication History

Whenever you hear:

"I've tried Methylphenidate. It didn't work."

your next question should be:

"Tell me exactly what happened."

Establish:

• preparation

• dose

• duration

• adherence

• therapeutic benefit

• duration of benefit

• adverse effects

• reason for discontinuation

You will frequently discover that apparent medication failure was actually:

inadequate dose

inadequate trial

poor adherence

insufficient duration of effect

or

good efficacy with unacceptable adverse effects.

Those are very different clinical situations.

Separate Drug Failure From Formulation Failure

This is one of the most useful prescribing distinctions.

Suppose modified-release Methylphenidate produces excellent symptom control from 8am until 2pm, after which the patient's ADHD symptoms return.

Do not automatically conclude:

"Methylphenidate has failed."

Methylphenidate may be working very well.

The problem is that the duration or release profile does not adequately match the patient's functional day.

Changing medication class without recognising this distinction may discard an otherwise effective treatment.

Separate Efficacy From Tolerability

Another patient might say:

"Lisdexamfetamine didn't suit me."

Perhaps it substantially improved attention, organisation and impulsivity but caused unacceptable appetite suppression.

That tells you something valuable.

The medication was effective but poorly tolerated.

Contrast that with a patient who experienced no meaningful improvement despite an adequate and well-tolerated trial.

That is insufficient efficacy.

Document these separately.

The Lowest Effective Dose Is More Important Than the Highest Tolerated Dose

Titration should not become a competition to reach the maximum licensed dose.

Imagine that a patient has:

clear functional improvement at a lower dose

but at the next dose:

little additional benefit + insomnia + appetite suppression + irritability.

The higher dose is not better treatment.

The aim is to find the dose at which meaningful benefit and tolerability are optimally balanced.

More Medication Is Not Always the Answer to Residual Difficulty

A patient may still:

• procrastinate

• struggle with organisation

• become overwhelmed by unrealistic workloads

• have relationship difficulties

• sleep badly

• experience anxiety

• struggle with autistic burnout or sensory overload

Do not automatically interpret every residual difficulty as undertreated ADHD.

Ask:

"Is the remaining problem actually responsive to more ADHD medication?"

Sometimes optimisation is appropriate.

Sometimes the answer is psychological intervention, environmental modification, sleep treatment, occupational support or treatment of a comorbid condition.

Non-stimulant Does Not Mean Safer

This misconception can influence both clinicians and patients.

Atomoxetine and Guanfacine have different risk profiles from stimulants, not an absence of risk.

Do not choose a non-stimulant merely because it sounds more conservative.

Choose it when its overall benefit-risk profile and place in the treatment pathway make it appropriate for that patient.

Do Not Turn Comorbidity Into a Prescribing Algorithm

Be cautious of rules such as:

"Anxiety means Atomoxetine."

"Tics mean Guanfacine."

"Autism means avoid stimulants."

"Substance misuse means never prescribe stimulants."

These statements remove the formulation from prescribing.

Comorbidity should influence medication choice, titration and monitoring, but the individual clinical circumstances remain important.

Practical Tips for Everyday Practice

Use the "Why This Medication?" Test

Before prescribing, ask yourself:

"Could I explain in two or three sentences why I have chosen this medication and formulation?"

If you cannot, your decision may not yet be sufficiently formulated.

A reasonable explanation might be:

"Methylphenidate is an appropriate first-line treatment in this patient's current pathway. A modified-release preparation is preferred because impairment extends across the school day and administration at school would be impractical. There are no identified clinical factors currently making this an inappropriate starting option."

That is a much stronger prescribing rationale than:

"Start Methylphenidate because they have ADHD."

Ask About the Functional Day

A useful question is:

"From what time until what time do you need your ADHD treatment to be helping?"

Then explore what happens during those hours.

Consider:

• waking and morning routine

• travel

• school

• university

• employment

• driving

• studying

• childcare

• household responsibilities

• social activities

• evening routines

This often makes formulation choice considerably clearer.

Establish Two to Four Treatment Targets

Before starting or changing medication, identify specific outcomes.

For example:

Work

Complete reports without repeatedly switching tasks.

Education

Remain engaged sufficiently to complete more classroom work.

Home

Complete the morning routine with fewer prompts.

Driving

Reduce impulsive and inattentive driving behaviours.

Organisation

Attend appointments and meet deadlines more consistently.

These targets give the subsequent review something concrete to assess.

Ask What Happened at Each Dose

When reviewing titration, avoid treating the medication history as one continuous block.

Ask:

"What happened at 20mg?"

"What changed at 30mg?"

"Was 40mg better than 30mg?"

"Which adverse effects appeared after the increase?"

This helps identify the point at which additional dose stopped producing additional benefit.

Ask When the Medication Wears Off

Patients often describe medication as:

"not strong enough."

But what they actually mean may be:

"It works brilliantly until 3pm."

Ask:

"When it is working, does it work well?"

Then:

"What time do you notice the benefit disappearing?"

This separates insufficient magnitude of effect from insufficient duration of effect.

Make One Important Change at a Time Where Possible

If you simultaneously:

• increase the ADHD medication

• change formulation

• start an antidepressant

• change sleep medication

and the patient feels substantially better or worse, interpretation becomes difficult.

Complex clinical situations sometimes require multiple changes, but where clinically feasible, sequential changes make treatment response easier to understand.

Ask About Appetite Properly

Do not simply ask:

"Is your appetite okay?"

Ask:

"Are you eating breakfast?"

"What happens at lunchtime?"

"Are you hungry in the evening?"

"Have portion sizes changed?"

"Has your weight changed?"

In children:

"Have parents noticed clothes becoming looser?"

"How is growth tracking?"

Specific questions produce clinically useful answers.

Ask About Sleep Before and After Medication

Document baseline sleep before prescribing.

Otherwise, when insomnia is reported later, you may not know whether it is:

• longstanding

• ADHD-related

• behavioural

• circadian

• anxiety-related

• medication-related

Knowing the baseline helps establish causality.

Check What the Patient Is Actually Taking

Never assume that the prescription equals the treatment.

Ask:

"What medication are you taking now?"

"What strength?"

"What time?"

"How many days did you miss last week?"

"Do you ever change the dose yourself?"

This is particularly important when a patient appears to have had several unsuccessful medication trials.

Common Pitfalls and Misconceptions

"The Strongest Medication Will Work Best"

There is no clinically useful hierarchy of ADHD medications based on being "stronger".

Treatment is about:

• response

• duration

• tolerability

• safety

• functional improvement

The most appropriate medication is the one producing the best overall treatment fit.

"Higher Dose Means Better Treatment"

Incorrect.

Once increasing the dose stops producing meaningful additional benefit, further escalation may simply increase adverse effects.

Titrate towards clinical optimisation, not towards the top of the dose range.

"Longer Acting Is Always Better"

Not necessarily.

Longer duration may be advantageous for many patients, but excessive duration can create difficulties such as unwanted evening effects or sleep problems.

The required duration should match the patient's functional needs.

"Shorter Acting Is More Flexible, So It Is Better"

Again, not necessarily.

Flexibility can come at the cost of:

• repeated dosing

• forgotten doses

• fluctuating coverage

• medication administration during school or work

• greater opportunities for misuse or diversion

There is no universally superior formulation.

"A Medication That Wears Off Early Has Failed"

Not if it works well while active.

That may represent a formulation or duration problem.

"Anxiety Means Avoid Stimulants"

Too simplistic.

Some patients experience increased anxiety.

Others experience less anxiety when their ADHD is effectively treated.

Understand the relationship between the anxiety and ADHD before making the decision.

"Tics Mean Stimulants Are Contraindicated"

Too simplistic.

Tic disorders and ADHD commonly coexist, and tic severity can fluctuate independently of medication.

Assess the individual clinical pattern.

"Autistic Patients Do Not Respond to ADHD Medication"

Incorrect.

Autistic people with coexisting ADHD may benefit from ADHD medication.

Some may require particularly careful titration and monitoring of tolerability, but autism itself should not be treated as an automatic reason to withhold appropriate ADHD treatment.

"A History of Substance Misuse Means Stimulants Can Never Be Used"

Again, too absolute.

Current substance use, dependence, stability, diversion risk, previous prescription misuse and the available monitoring arrangements all matter.

Some situations will make stimulant prescribing inappropriate.

Others may allow carefully considered treatment.

The decision requires an individual risk-benefit assessment.

"If Medication Works, the Diagnosis Must Be Correct"

Medication response does not confirm ADHD.

Equally, non-response does not exclude ADHD.

Do not use pharmacological response as a retrospective diagnostic test.

Advice for Newly Qualified Doctors

Know the Standard Pathway Before Attempting Exceptions

Become confident with routine evidence-based treatment selection first.

Know:

• usual first-line treatments

• what constitutes an adequate trial

• when switching is appropriate

• where non-stimulants fit

• baseline assessment

• titration

• monitoring

• important contraindications and cautions

Once you understand the standard pathway, unusual cases become easier to recognise.

Check the Preparation, Not Just the Drug Name

"Methylphenidate" is not sufficient information when formulation matters.

Know exactly what preparation the patient is taking.

Modified-release preparations should not automatically be regarded as interchangeable simply because they contain the same active drug and total milligram dose.

Check current prescribing guidance when switching preparations.

Do Not Prescribe From Memory When You Are Unsure

There is no prize for remembering every dose, interaction or formulation characteristic.

Check current:

• NICE guidance

• BNF or BNF for Children

• Summary of Product Characteristics

• relevant local guidance

Good prescribing includes knowing when to verify information.

Learn to Say "I Need to Review This Before Changing It"

You do not have to make an immediate medication change simply because a patient asks for one.

This is particularly appropriate when:

• previous treatment history is unclear

• physical observations are concerning

• there may be an interaction

• substance misuse is relevant

• the requested treatment is outside the usual pathway

• the diagnosis or formulation requires reconsideration

Clinical caution is preferable to an inadequately informed prescription.

Document the Reason, Not Just the Decision

Instead of:

"Switch to Lisdexamfetamine."

document why.

For example:

"Methylphenidate has been taken consistently at an appropriate dose for an adequate duration. Although tolerated, there has been insufficient improvement in attention, task completion or occupational functioning. Following discussion of alternatives, an appropriate trial of the alternative stimulant class is planned."

That record will be valuable to whoever reviews the patient next.

Know When to Ask for Help

Seek senior or specialist advice when you encounter:

• significant cardiovascular disease

• psychosis

• bipolar disorder

• significant substance misuse

• complex eating pathology

• substantial polypharmacy

• unusual or severe adverse effects

• repeated treatment failure

• complex combination treatment

• prescribing outside usual licensing or guideline recommendations

• significant diagnostic uncertainty

Competence includes recognising the limits of routine prescribing.

Situations Requiring Particular Clinical Judgement

Good Response but Significant Appetite Suppression

This is not automatically treatment success or treatment failure.

Ask:

• How substantial is the ADHD benefit?

• How significant is the appetite change?

• Is weight changing?

• In a child, what is happening to growth?

• Can timing or formulation be optimised?

• Is the adverse effect persistent?

• Is another medication strategy preferable?

The decision depends on the balance between benefit and harm.

Excellent Morning Response but Poor Afternoon Coverage

Do not automatically increase the dose.

First determine whether the issue is duration.

A formulation change or other appropriately planned strategy may make more sense than simply increasing exposure.

Anxiety Appears During Titration

Establish:

• Was anxiety present before treatment?

• Did it clearly worsen after a dose increase?

• Does it occur while medication is active?

• Is it associated with physiological overstimulation?

• Is there an independent anxiety disorder?

• Has improved ADHD functioning actually reduced anxiety elsewhere?

The temporal relationship is often crucial.

Tics Become More Noticeable

Do not immediately assume causation.

Review:

• baseline tic history

• natural fluctuation

• timing relative to treatment

• dose relationship

• severity

• distress

• functional impact

• ADHD benefit

Then make a proportionate decision.

Previous Substance Misuse

Avoid both extremes:

"They have ADHD, so prescribe normally."

and:

"They once misused drugs, so ADHD medication is impossible."

Undertake an individual risk assessment.

Consider current stability, substance use, diversion risk, formulation, storage, monitoring and reasonable alternatives.

The Patient Requests a Particular Medication

Patients increasingly arrive having researched ADHD treatment online.

They may ask specifically for:

• Lisdexamfetamine

• a particular Methylphenidate preparation

• immediate-release medication

• a non-stimulant

Explore why.

Perhaps they have a legitimate concern about duration or adverse effects.

Perhaps a relative responded well to that medication.

Perhaps they have misunderstood something online.

Perhaps there are misuse concerns.

Listen to the request without either automatically agreeing or dismissing it.

Shared decision-making means incorporating patient preference into an evidence-based clinical decision.

Several Medications Have "Failed"

This is a particularly important point to stop and think.

Before moving to increasingly complex treatment, reconstruct every previous trial.

Ask:

Was the diagnosis robust?

Was the medication taken?

Was the dose adequate?

Was the duration adequate?

Was the formulation appropriate?

What actually improved?

Why was it stopped?

What impairment remains?

Could something else now be driving that impairment?

Repeated medication failure should increase the quality of your formulation, not merely the complexity of your prescription.

A Practical Five-Minute Medication Choice Framework

When reviewing a relatively straightforward patient, use five domains.

1. Pathway

What options are guideline-supported at this stage?

2. Previous Response

What have previous medication trials taught us?

3. Patient Factors

What physical health, mental health, appetite, sleep, substance use or interaction issues matter?

4. Functional Fit

When does the medication need to work, and which formulation best matches that requirement?

5. Preference and Practicality

What does the patient prefer, and can they realistically follow the proposed regimen?

Then formulate your recommendation:

"I recommend X because A, B and C. We will assess it against targets D and E while monitoring F and G. If it does not provide sufficient benefit or causes unacceptable adverse effects, the next reasonable option would be H."

That is a clinically meaningful medication plan.

The Question to Ask Before Every Medication Change

Before changing treatment, ask yourself:

"What problem am I trying to solve with this change?"

If the answer is:

"The medication works but wears off too early,"

solve the duration problem.

If the answer is:

"There has been no meaningful response despite an adequate trial,"

solve the efficacy problem.

If the answer is:

"It works but the adverse effects are unacceptable,"

solve the tolerability problem.

If the answer is:

"They keep forgetting the afternoon dose,"

solve the adherence problem.

If the answer is:

"Their concentration remains poor because they sleep four hours each night,"

do not assume that increasing ADHD medication solves the correct problem.

Precise problems produce better prescribing decisions.

Final Clinical Message

Choosing the right ADHD medication is rarely about identifying one universally superior drug.

It is about achieving the best fit between the medication and the patient.

That means integrating:

evidence and guidelines

with

clinical formulation

with

previous treatment response

with

physical and psychiatric safety

with

the patient's functional day

with

practicality and adherence

and

patient preference.

Be particularly careful to distinguish:

ineffective drug

from

inadequate dose

from

inadequate duration of trial

from

wrong formulation

from

poor adherence

from

unacceptable adverse effects

from

a problem that medication was never going to solve.

If you make those distinctions well, medication selection becomes much more rational.

The central principle is:

Choose the medication and formulation that best match the patient's clinical needs, functional requirements, safety profile and preferences — then test that choice through careful titration, monitoring and review.5. Summary

Choosing ADHD medication is a process of clinical matching rather than simply following a drug hierarchy. Guidelines provide the treatment pathway, but the final prescribing decision should reflect the individual patient’s needs, previous treatment response, safety considerations, functional demands and preferences.

The first step is to establish where the patient is in the treatment pathway and which medications are appropriate according to current clinical guidance. From there, treatment should be individualised.

A useful medication-selection framework is:

Treatment pathway → treatment targets → required duration → previous response → safety factors → practical fit → patient preference

Medication choice should begin with a clear understanding of what needs to improve. Functional targets may include classroom engagement, work completion, impulsivity, organisation, driving, home routines or evening parenting responsibilities.

The clinician should also consider when symptom control is required. A medication that works well but does not cover the clinically important part of the patient’s day may be pharmacologically effective but functionally inadequate.

Previous medication trials should be analysed carefully. Statements such as “Methylphenidate did not work” are insufficient without knowing:

• formulation

• dose

• duration

• adherence

• therapeutic response

• duration of benefit

• adverse effects

• reason for stopping

Apparent treatment failure may actually represent:

inadequate dose

inadequate duration of trial

poor adherence

wrong formulation

insufficient duration of effect

unacceptable adverse effects

or

treatment of the wrong clinical target.

This distinction is essential because each problem requires a different response.

Immediate-release and modified-release preparations should be chosen according to the patient’s functional requirements, adherence, daily routine and risk profile. Modified-release Methylphenidate preparations are not necessarily interchangeable because they can have different release characteristics and clinical durations.

Physical health should form part of medication selection. Cardiovascular history, pulse, blood pressure, weight, growth where appropriate, appetite, sleep and other medical conditions may influence treatment choice and monitoring.

Psychiatric comorbidity should also inform prescribing, but rigid rules should be avoided. Anxiety, depression, autism, tic disorders, substance misuse and other conditions may influence treatment choice and monitoring without automatically determining which medication can or cannot be used.

A history of substance misuse does not automatically exclude stimulant treatment, but it does require careful assessment of current substance use, stability, diversion risk, prescribing arrangements and safer alternatives.

Patient preference is an important part of shared decision-making. The clinician should explain the reasonable treatment options, likely benefits, adverse effects, uncertainties, monitoring requirements and practical considerations. Shared decision-making does not mean prescribing any requested medication regardless of clinical appropriateness.

Treatment should be titrated towards optimal clinical benefit, not towards the highest available dose. The correct dose is the dose at which meaningful improvement in symptoms and functioning is achieved with acceptable adverse effects.

Residual difficulties should not automatically lead to further medication escalation. Persistent problems may reflect environmental factors, poor sleep, anxiety, depression, autism-related difficulties, organisational habits or other issues that may require non-pharmacological intervention or treatment of comorbidity.

When several medications appear to have failed, clinicians should return to the formulation. Reconsider diagnostic certainty, adherence, adequacy of previous trials, treatment targets, sleep, substance use, comorbidity, environmental demands and patient expectations before moving to increasingly complex pharmacological strategies.

A medication change should always answer a specific clinical problem.

If treatment:

works but wears off too early → consider duration or formulation.

If treatment:

produces insufficient benefit despite an adequate trial → consider alternative treatment.

If treatment:

works but causes unacceptable adverse effects → address tolerability.

If treatment:

is taken inconsistently → address adherence.

If the remaining difficulty is not primarily caused by ADHD → treat the correct problem rather than simply increasing ADHD medication.

The central principle is:

There is no single “best” ADHD medication. The right choice is the medication and formulation that provide the best evidence-based fit for the individual patient’s clinical needs, functional requirements, safety profile, treatment history and preferences.

Good prescribing therefore requires clinicians to combine:

guideline knowledge

with

clinical formulation

with

shared decision-making

and then test the decision through careful titration, monitoring and review.

6. Further Reading

The following resources are particularly useful for consolidating the principles involved in choosing ADHD medication, including treatment sequencing, stimulant versus non-stimulant selection, interpretation of previous medication trials, formulation choice, comorbidity, tolerability and shared decision-making.

Relevant NICE Guidance

National Institute for Health and Care Excellence (NICE)

Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NG87)

This remains the principal UK guideline for ADHD treatment and should be the starting point for medication selection in UK clinical practice.

The sections on medication choice, baseline assessment, dose titration, monitoring, adverse effects and medication review are particularly relevant.

NICE provides the core treatment sequence for children, young people and adults and emphasises that medication choice should take account of clinical circumstances rather than being based solely on the diagnostic label.

The guideline's evidence review also concluded that the medications with the most convincing clinically important benefit included Methylphenidate, Atomoxetine, Lisdexamfetamine, Dexamfetamine and Guanfacine, while other agents should generally remain within specialist ADHD services.

NICE NG87: Attention deficit hyperactivity disorder – diagnosis and management

For practical prescribing, NICE should be used alongside the BNF or BNF for Children and the current Summary of Product Characteristics for the specific preparation.

Australian Evidence-Based Clinical Practice Guideline for ADHD

Australian ADHD Professionals Association (AADPA).

Australian Evidence-Based Clinical Practice Guideline for Attention Deficit Hyperactivity Disorder.

This is one of the most useful international resources for understanding medication choice.

The guideline recommends shared decision-making and individual optimisation of medication. It supports stimulants as first-line pharmacological treatment in most children aged 6 years and over, adolescents and adults unless health considerations make them unsuitable. If one stimulant is ineffective or poorly tolerated, the alternative stimulant class should generally be considered before moving to non-stimulant medication.

It is particularly valuable for this lesson because it discusses:

• stimulant versus non-stimulant choice

• short-acting versus long-acting formulations

• dose optimisation

• adverse-effect considerations

• comorbidity

• drug interactions

• shared decision-making

• circumstances requiring additional caution

The guideline also notes that available evidence does not generally justify automatically choosing a different ADHD medication solely because a co-occurring condition is present. Instead, careful assessment, consideration of interactions, slower titration where appropriate and closer monitoring may be required.

Australian Evidence-Based Clinical Practice Guideline for ADHD

Canadian ADHD Practice Guidelines

Canadian ADHD Resource Alliance (CADDRA).

Canadian ADHD Practice Guidelines, 4.1 Edition.

These guidelines provide a highly practical approach to medication selection across the lifespan.

CADDRA divides stimulant medication into Methylphenidate-based and amphetamine-based groups and emphasises that individual response to one class does not reliably predict response to the other. Therefore, inadequate response to one stimulant class should generally lead to consideration of an adequate trial of the other before moving to second-line treatments.

CADDRA also highlights practical reasons why longer-acting preparations may often be preferred, including improved adherence, longer symptom coverage and lower misuse potential relative to some shorter-acting preparations.

This is especially useful reading for understanding:

• medication comparisons

• duration of action

• stimulant classes

• formulation selection

• comorbidity

• substance misuse considerations

• practical prescribing decisions

CADDRA Canadian ADHD Practice Guidelines

Landmark Comparative Evidence

Cortese et al. – Network Meta-analysis

Cortese S, Adamo N, Del Giovane C, et al.

Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727–738.

This is one of the most important papers for understanding comparative ADHD pharmacotherapy.

The analysis included 133 double-blind randomised controlled trials, involving more than 10,000 children and adolescents and more than 8,000 adults in the primary short-term efficacy analyses.

The study found that several ADHD medications were superior to placebo for short-term symptom reduction. When both efficacy and tolerability were considered, the findings supported Methylphenidate in children and adolescents and amphetamines in adults as preferred first-choice medications at a population level.

However, this should not be interpreted as meaning that every adult should receive an amphetamine or every child should receive Methylphenidate.

The clinically important lesson is:

Population-level comparative evidence informs medication choice, but individual treatment still requires titration, monitoring and assessment of tolerability and functional response.

The review also found insufficient evidence for the planned longer-term 26- and 52-week analyses, highlighting the importance of ongoing clinical review rather than assuming that short-term trial results answer every long-term prescribing question.

Cortese et al. – Comparative efficacy and tolerability of ADHD medications

Contemporary Adult Pharmacotherapy Evidence

Comparative Pharmacological Treatment in Adults

Pharmacologic treatment of attention deficit hyperactivity disorder in adults: a systematic review and network meta-analysis.

This systematic review specifically examined pharmacological ADHD treatment in adults, including clinical response, quality of life, executive functioning, driving behaviour and adverse outcomes.

It is useful for clinicians because it illustrates that medication choice should not be based solely on change in ADHD symptom scores. Broader outcomes such as functioning, acceptability and adverse-event-related discontinuation also matter.

Adult ADHD pharmacotherapy network meta-analysis

Recent Adult Treatment Network Meta-analysis

Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis.

This more recent systematic review included 113 randomised controlled trials involving 14,887 adults and compared pharmacological, psychological and neurostimulatory interventions.

It is particularly valuable for placing medication choice within the wider treatment landscape and for reinforcing the distinction between efficacy and acceptability.

The paper is useful supplementary reading once clinicians are comfortable with the core NICE pathway.

Recent adult ADHD treatment network meta-analysis

European Consensus Guidance

Kooij et al.

Kooij JJS, Bijlenga D, Salerno L, et al.

Updated European Consensus Statement on Diagnosis and Treatment of Adult ADHD. European Psychiatry. 2019;56:14–34.

This consensus statement is particularly useful for clinicians prescribing for adults.

It reviews ADHD across the lifespan and addresses diagnosis and treatment from a European clinical perspective. It is valuable for understanding medication within the wider context of:

• functional impairment

• psychiatric comorbidity

• multimodal management

• psychoeducation

• adult-specific treatment considerations

The statement was developed by a large international expert group and aims to integrate research evidence with clinical experience.

Updated European Consensus Statement on Adult ADHD

World Federation of ADHD International Consensus Statement

Faraone SV, Banaschewski T, Coghill D, et al.

The World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions About the Disorder. Neuroscience & Biobehavioral Reviews. 2021;128:789–818.

This consensus statement is useful for understanding the broader evidence base underpinning ADHD treatment.

The authors included large studies and meta-analyses and produced 208 evidence-supported conclusions about the nature, outcomes and treatment of ADHD.

For medication selection, it is particularly useful as a background resource when discussing:

• evidence that ADHD medications are effective

• differences between medication classes

• common misconceptions about stimulant treatment

• treatment benefits and risks

World Federation of ADHD International Consensus Statement

Prescribing References

British National Formulary and BNF for Children

These should be used alongside clinical guidelines whenever ADHD medication is prescribed.

They are particularly important for confirming:

• licensed indications

• starting doses

• titration schedules

• maximum doses

• contraindications

• cautions

• interactions

• adverse effects

• monitoring requirements

Medication-selection decisions should not rely on remembered dose ranges when current authoritative prescribing information is readily available.

Summary of Product Characteristics

The current SmPC for the specific preparation should also be consulted when questions arise about:

• administration

• formulation characteristics

• food effects

• switching products

• interactions

• missed doses

• discontinuation

• special populations

• uncommon adverse effects

This is particularly important with modified-release stimulant preparations, where products containing the same active ingredient may have different release characteristics.

Important Evidence-Based Principles for Medication Choice

The literature reinforces several practical messages.

Population averages do not determine individual response

Comparative trials can tell us which medications perform best on average.

They cannot tell us with certainty which medication will work best for an individual patient.

One stimulant class failing does not mean the other will fail

Clinical guidelines and CADDRA guidance emphasise the value of trialling the alternative stimulant class where the first has been adequately tried but has not produced sufficient benefit.

Efficacy and tolerability must be considered together

A medication can produce excellent symptom reduction but still be a poor treatment choice if adverse effects are unacceptable.

The Cortese network meta-analysis specifically compared both efficacy and tolerability, reinforcing this principle.

Formulation matters

Medication selection includes duration, release profile and practical administration as well as the active drug.

Comorbidity should modify assessment rather than create automatic prescribing rules

The Australian guideline notes limited evidence for automatically choosing different ADHD medications purely on the basis of many co-occurring disorders and instead supports more careful assessment and monitoring.

Shared decision-making is central

Medication choice and dose should be optimised for the individual after discussion of benefits, risks and preferences.

Recommended Reading Priorities

For clinicians with limited time, the following sequence is particularly useful:

1. NICE NG87

Essential for understanding the UK treatment pathway and medication sequencing.

2. BNF or BNF for Children

Essential for safe day-to-day prescribing.

3. Cortese et al. (2018)

The key comparative medication meta-analysis and particularly useful for understanding why treatment selection should balance efficacy and tolerability.

4. Australian ADHD Clinical Practice Guideline

Excellent for detailed discussion of medication choice, shared decision-making and comorbidity.

5. CADDRA Canadian ADHD Practice Guidelines

Particularly useful for stimulant-class selection, formulations and practical prescribing.

6. Kooij et al. European Consensus Statement

Recommended for clinicians working predominantly with adults.

7. World Federation of ADHD International Consensus Statement

Useful for consolidating the wider evidence base and addressing misconceptions about ADHD pharmacotherapy.

Final Reading Message

The research literature does not identify one medication that is universally best for ADHD.

Instead, it supports a structured approach in which clinicians combine:

guideline-based treatment sequencing

with

comparative evidence

with

individual treatment response

with

tolerability and safety

with

functional requirements

and

patient preference.

The most important lesson from the literature is therefore not:

"Which medication has the largest average effect?"

It is:

"How should population-level evidence be translated into the safest and most effective individual treatment decision?"

Guidelines identify the appropriate options.

Trials tell us what tends to work.

Previous medication response tells us what happened in this patient.

Careful titration and monitoring tell us whether the choice was correct.

Together, these form the basis of rational ADHD medication selection.

7. Knowledge Check

The following questions are designed to test the clinical reasoning involved in selecting ADHD medication rather than simple recall of individual drug characteristics.

Select the single best answer for each question.

Question 1

A 32-year-old man has recently been diagnosed with ADHD. Medication is indicated. He has no significant physical-health contraindications and has never previously received ADHD medication.

According to the usual NICE treatment pathway, which pharmacological options would generally be considered first-line for an adult?

A. Atomoxetine or Guanfacine
B. Methylphenidate or Lisdexamfetamine
C. Guanfacine or Clonidine
D. Atomoxetine only

Correct Answer: B

Explanation

A. Incorrect. Atomoxetine is an important non-stimulant option, but it is not generally the routine first-line pharmacological treatment for an adult when appropriate stimulant treatment can be used. Guanfacine does not occupy the same routine position in the adult NICE pathway.

B. Correct. NICE identifies Methylphenidate or Lisdexamfetamine as first-line pharmacological treatment options for adults with ADHD when medication is indicated.

C. Incorrect. Neither Guanfacine nor Clonidine represents the routine first-line adult treatment pathway.

D. Incorrect. Atomoxetine is not the only pharmacological treatment available to adults and would not usually be selected ahead of appropriate first-line stimulant treatment without a clinical reason.

The key principle is:

Know the guideline-supported options first, then individualise the choice between them.

Question 2

A 13-year-old has been taking modified-release Methylphenidate. His teachers report substantial improvement in attention and impulsivity throughout the morning. Symptoms consistently return at approximately 2pm and homework remains difficult.

What is the most useful initial interpretation?

A. Methylphenidate has definitely failed.
B. The ADHD diagnosis is probably incorrect.
C. The medication may be effective, but its duration or release profile may not adequately match the patient's functional day.
D. The dose should automatically be increased to the maximum permitted dose.

Correct Answer: C

Explanation

A. Incorrect. The medication is producing substantial benefit while it is active. Calling this complete drug failure loses important clinical information.

B. Incorrect. Medication duration does not determine diagnostic validity.

C. Correct. This is a classic situation in which clinicians should distinguish drug efficacy from duration of effect. The active medication may be appropriate while the formulation or duration of coverage requires reconsideration.

D. Incorrect. Increasing the dose should not be automatic. The problem needs to be identified before deciding how to solve it.

The key question is:

"When the medication is working, does it work well?"

If the answer is yes, think about formulation and duration before assuming pharmacological non-response.

Question 3

A 24-year-old reports that Methylphenidate "didn't work". Further questioning reveals that he took a low starting dose for four days, missed two doses and then stopped treatment because he could not notice any difference.

What is the most appropriate conclusion?

A. He has demonstrated genuine non-response to Methylphenidate.
B. He has not received an adequate therapeutic trial from which efficacy can reasonably be judged.
C. He should immediately receive a non-stimulant.
D. His lack of response suggests that he does not have ADHD.

Correct Answer: B

Explanation

A. Incorrect. Four days at a low starting dose with inconsistent adherence does not establish pharmacological non-response.

B. Correct. Before describing medication as ineffective, establish whether an appropriate dose was reached, whether treatment was taken consistently and whether the trial was sufficiently long to evaluate response.

C. Incorrect. Moving immediately to a non-stimulant would be premature if the previous stimulant trial was inadequate.

D. Incorrect. Medication response is not a diagnostic test for ADHD.

This illustrates an important prescribing principle:

A medication that has been prescribed is not necessarily a medication that has been adequately tried.

Question 4

A 40-year-old woman takes long-acting ADHD medication. Her attention, organisation and task completion at work have improved substantially. Following a dose increase, there is little additional functional benefit but she develops significant insomnia and appetite suppression.

What is the best approach?

A. Continue increasing the dose because higher doses are usually more effective.
B. Maintain the higher dose because adverse effects demonstrate adequate drug exposure.
C. Review whether the previous lower dose provided a better balance between benefit and adverse effects.
D. Stop all ADHD treatment permanently.

Correct Answer: C

Explanation

A. Incorrect. Titration should not aim for the highest possible dose. Once additional dose stops producing meaningful additional benefit, further escalation may simply increase adverse effects.

B. Incorrect. Adverse effects are not therapeutic targets.

C. Correct. The objective is to identify the dose that produces the best overall balance between meaningful functional improvement and tolerability. A lower dose may therefore represent better treatment.

D. Incorrect. The patient previously obtained substantial benefit. The emergence of adverse effects at a higher dose does not necessarily mean all ADHD medication should be abandoned.

Remember:

The optimal dose is not necessarily the maximum tolerated dose.

Question 5

A 29-year-old with ADHD also has an anxiety disorder. A junior doctor states that stimulant medication should automatically be avoided because stimulants always worsen anxiety.

Which response is most accurate?

A. Correct. Any anxiety disorder is an absolute contraindication to stimulant medication.
B. Correct. All patients with ADHD and anxiety should receive Atomoxetine instead.
C. Incorrect. The relationship between ADHD, anxiety and medication should be assessed individually rather than applying an automatic prescribing rule.
D. Incorrect, because stimulant medication always improves anxiety.

Correct Answer: C

Explanation

A. Incorrect. The presence of an anxiety disorder does not automatically make stimulant treatment inappropriate.

B. Incorrect. Atomoxetine may be appropriate in some patients, but anxiety alone does not create a universal rule that Atomoxetine must be selected.

C. Correct. Anxiety should form part of the clinical formulation. Some patients may experience increased anxiety during stimulant treatment, while others may experience reduced anxiety when improved ADHD control makes everyday life less chaotic and overwhelming.

D. Incorrect. The opposite absolute statement is equally inappropriate. Stimulants do not invariably improve anxiety.

The important principle is:

Comorbidity should influence medication selection and monitoring without becoming a simplistic prescribing algorithm.

Question 6

A 27-year-old with well-established ADHD has a history of cocaine dependence but reports two years of abstinence and remains engaged with substance-misuse services. He asks whether his history means that stimulant medication can never be considered.

What is the best response?

A. Any previous substance misuse permanently contraindicates all stimulant treatment.
B. His history is irrelevant because ADHD has been diagnosed.
C. An individual risk-benefit assessment is required, including current substance use, stability, diversion risk, previous prescription misuse, formulation and monitoring arrangements.
D. He should automatically receive immediate-release stimulant medication because it is easier to adjust.

Correct Answer: C

Explanation

A. Incorrect. A history of substance misuse should not automatically be converted into an absolute lifelong prohibition without considering the individual circumstances.

B. Incorrect. A genuine ADHD diagnosis does not remove the potential risks associated with substance misuse, medication misuse or diversion.

C. Correct. This situation requires careful clinical judgement. Current stability, substance use, previous behaviour, diversion risk, medication formulation, storage and monitoring all contribute to the decision.

D. Incorrect. Immediate-release medication may create additional misuse or diversion concerns in some circumstances and should not automatically be selected.

The appropriate approach is neither:

"ADHD diagnosis means prescribe normally"

nor:

"Substance misuse history means never prescribe."

It is an individualised risk-benefit formulation.

Question 7

A 10-year-old autistic child has clinically significant ADHD. A colleague suggests that ADHD medication should not be offered because autistic children do not respond to stimulants.

Which statement is most accurate?

A. Autism automatically excludes pharmacological ADHD treatment.
B. ADHD medication may still be effective, although careful titration and monitoring of tolerability may be particularly important.
C. Only Guanfacine can be used when ADHD coexists with autism.
D. Medication should be used primarily to reduce autistic traits.

Correct Answer: B

Explanation

A. Incorrect. Autism does not automatically exclude appropriate pharmacological treatment of coexisting ADHD.

B. Correct. Autistic patients with ADHD may benefit from ADHD medication. Individual tolerability can vary, and careful titration and monitoring may be particularly important where there are existing difficulties involving sleep, eating, sensory sensitivity or communication of internal experiences.

C. Incorrect. There is no universal rule that Guanfacine is the only medication that can be used in autistic patients with ADHD.

D. Incorrect. The treatment target is the patient's clinically significant ADHD symptoms and associated impairment, not autistic characteristics themselves.

The principle is:

Treat the ADHD when treatment is indicated, while adapting prescribing to the individual patient.

Question 8

A 35-year-old nurse with ADHD works rotating shifts. She has difficulty remembering medication taken several times during the day and cannot reliably take medication at fixed times while working.

Which factor should have particular influence on medication selection?

A. Only which drug has the largest average effect size in research trials.
B. The practicality of the regimen, including formulation, duration of effect and likelihood of adherence.
C. Medication cost alone.
D. Her occupation is irrelevant once ADHD has been diagnosed.

Correct Answer: B

Explanation

A. Incorrect. Population-level efficacy evidence is important, but it does not determine whether a particular regimen will work in an individual's daily life.

B. Correct. Medication needs to be practically usable. Formulation, timing, duration and adherence should be considered alongside efficacy and safety.

C. Incorrect. Cost and local prescribing arrangements may sometimes be relevant, but medication selection should not be based on cost alone.

D. Incorrect. Occupational demands can be highly relevant because they influence when symptom control is required and whether the proposed regimen is practical.

A medication cannot produce reliable benefit if the patient cannot realistically follow the treatment plan.

Question 9

A 38-year-old has received several ADHD medications with apparently poor results. Despite further dose increases, she continues to report severe concentration difficulties. Further assessment reveals that she is sleeping approximately four hours each night and has developed a significant depressive episode.

What is the most appropriate next step in clinical reasoning?

A. Continue escalating ADHD medication until concentration normalises.
B. Conclude that ADHD medication never works in adults with depression.
C. Revisit the clinical formulation and consider whether sleep deprivation and depression are contributing substantially to the residual impairment.
D. Assume the ADHD diagnosis must be incorrect.

Correct Answer: C

Explanation

A. Incorrect. More ADHD medication is not necessarily the solution to impairment driven substantially by another clinical problem.

B. Incorrect. Depression does not mean ADHD medication can never be effective.

C. Correct. When several treatments appear unsuccessful, clinicians should return to the formulation. Poor sleep, depression, anxiety, substance use, environmental demands and other conditions may contribute to persistent concentration and executive difficulties.

D. Incorrect. Reconsidering the formulation does not mean automatically abandoning the ADHD diagnosis. ADHD and other causes of cognitive impairment can coexist.

A useful rule is:

Repeated treatment failure should make the formulation more sophisticated, not simply the prescription more complicated.

Question 10

Which of the following best represents high-quality medication selection for ADHD?

A. Choose the medication considered strongest and titrate towards the maximum dose.
B. Follow the guideline hierarchy without considering individual circumstances.
C. Ask the patient which medication they want and prescribe their preferred option.
D. Identify guideline-supported options and then integrate treatment targets, required duration, previous response, physical and psychiatric factors, safety, adherence, practical circumstances and patient preference.

Correct Answer: D

Explanation

A. Incorrect. There is no clinically useful concept of simply choosing the "strongest" ADHD medication. Higher doses are also not inherently better.

B. Incorrect. Guidelines provide the essential framework but do not replace individual clinical judgement.

C. Incorrect. Patient preference matters, but shared decision-making does not mean prescribing any requested medication regardless of clinical appropriateness.

D. Correct. Good medication selection combines evidence-based treatment sequencing with individual formulation. The medication and formulation should fit the patient's clinical needs, functional requirements, treatment history, safety profile and preferences.

This captures the central principle of the lesson:

Do not ask which ADHD medication is best. Ask which medication is the best evidence-based fit for this patient at this stage of treatment.

Knowledge Check Summary

Choosing ADHD medication involves substantially more than selecting a drug from a treatment hierarchy.

The clinician should first identify the guideline-supported options and then individualise treatment according to:

treatment targets

required duration of symptom control

previous medication response

physical health

psychiatric comorbidity

appetite and sleep

substance use

misuse and diversion risk

adherence

practical circumstances

and

patient preference.

One of the most important skills is correctly interpreting apparent medication failure.

Always distinguish:

inadequate dose

from

inadequate duration of trial

from

poor adherence

from

insufficient duration of effect

from

formulation mismatch

from

genuine pharmacological non-response

from

unacceptable adverse effects

from

persistent impairment that is not primarily being driven by ADHD.

These distinctions determine the next treatment decision.

Comorbidity should modify clinical reasoning rather than create automatic prescribing rules. Anxiety, autism, tic disorders and substance-use disorders require individual assessment rather than simplistic conclusions about which medication must or must not be used.

Formulation matters because medication needs to fit the patient's functional day. A drug that works well but wears off before clinically important activities have finished may require reconsideration of duration or formulation rather than abandonment of an otherwise effective medication.

Similarly, treatment should be titrated towards the best balance of benefit and tolerability, not towards the highest possible dose.

When treatment repeatedly appears unsuccessful, return to the clinical formulation before escalating pharmacological complexity.

At each medication decision, ask:

Where is this patient in the treatment pathway?

What exactly are we trying to improve?

When does treatment need to work?

What have previous trials taught us?

What clinical factors influence safety and tolerability?

Can the patient realistically follow this regimen?

What does the patient prefer?

How will we know whether our choice has worked?

The goal is not to make the perfect medication choice at the first attempt.

The goal is to make a rational, evidence-based and individualised choice, evaluate it properly, learn from the response and adjust treatment accordingly.